DUBAI-INTERNET-CITY
20.10.2015 13:21:15 CEST | Business Wire | Press release
Dubai Internet City (DIC) , the official partner for the Smart City App Hack, has announced the competition’s 10 finalists; Boxit.com, Ithal, Einvite, Carpool Arabia, World Spotlight, D2D Auto Services, LupUp, GPSShield, MyGreenRank and App3ad. The competition is part of DIC’s role as a Strategic Partner for Smart Dubai, to support the development of UAE start-ups and app developers and bring together the tech community and foster innovation and creativity.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151020005876/en/
Over the past five months, developers and entrepreneurs have had the chance to be involved in the building of a truly Smart City and have created and developed apps, mentored by a global team of tech experts. Applicants were invited to submit app ideas based around five Smart themes; Urban Mobility, Energy and Emissions, Culture and Tourism, Retail and Shopping and Collaborative City, ahead of selection on 3 October.
The winning team will be awarded a trip to Barcelona to pitch their app at the Smart City Expo in November, as well as in5 membership, and second and third place will be awarded four months of membership at in5, and the chance to be selected as one of the finalists to pitch their apps in Barcelona. The winner of the Smart City Expo will be invited to pitch at the MasterCard Masters of Code in Silicon Valley.
Majed Al Suwaidi, Managing Director of Dubai Internet City and Dubai Outsource Zone said;
“The Smart City App Hack competition is part of our wider focus on supporting the development of UAE start-ups, entrepreneurs, mobile application and web developers. Competitions such as this are instrumental in achieving Dubai’s wider smart objectives and will contribute to the government’s vision to make Dubai the smartest place in the world by 2017.”
To register for the competition, please visit http://dubai.smartcityapphack.com/
About Dubai Internet City
Dubai Internet City (DIC), part of TECOM Group, a member of Dubai Holding, is the Middle East and North Africa’s largest ICT hub. Since the year 2000, DIC has successfully developed a prosperous ecosystem for technology organisations and today is home to Fortune 500 listed companies and multinationals as well as some of the region’s most dynamic and successful technology SMEs and start-ups from all elements of the ICT value chain.
DIC provides a wide range of facilities including state-of-the-art offices, a robust IT infrastructure, 24-hour security, retail services and hotels, spread across the business park’s unique and tranquil landscape; an environment that helps ICT businesses develop, innovate and grow.
For more information, please visit: www.dubaiinternetcity.com .
*Source: ME NewsWire
View source version on businesswire.com: http://www.businesswire.com/news/home/20151020005876/en/
Contact:
For Dubai Internet City
Alexa Hooft Graafland, +971-55-559-7404
AHooftGraafland@bell-pottinger.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom